Low Cortisone as a Novel Predictor of the Low-Renin Phenotype.

aldosterone cortisol cortisone low-renin hypertension

Journal

Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997

Informations de publication

Date de publication:
06 Apr 2024
Historique:
received: 18 12 2023
medline: 8 4 2024
pubmed: 8 4 2024
entrez: 8 4 2024
Statut: epublish

Résumé

A large proportion of patients with low-renin hypertension (LRH) correspond to primary aldosteronism (PA). However, some of these subjects have low to normal aldosterone. Since low renin is driven by excessive mineralocorticoids or glucocorticoids acting on mineralocorticoid receptors (MRs), we hypothesize that a low-cortisone condition, associated classically with 11βHSD2 deficiency, is a proxy of chronic MR activation by cortisol, which can also lead to low renin, elevated blood pressure, and renal and vascular alterations. To evaluate low cortisone as a predictor of low renin activity and its association with parameters of kidney and vascular damage. A cross-sectional study was carried out in 206 adult subjects. The subjects were classified according to low plasma renin activity (<1 ng/mL × hours) and low cortisone (<25th percentile). Plasma renin activity was associated with aldosterone (r = 0.36; This is the first study showing that low cortisone is a predictor of a low-renin condition. Low cortisone also predicted surrogate markers of vascular and renal damage. Since the aldosterone to renin ratio is used in the screening of PA, low cortisone values should be considered additionally to avoid false positives in the aldosterone-renin ratio calculation.

Identifiants

pubmed: 38586159
doi: 10.1210/jendso/bvae051
pii: bvae051
pmc: PMC10998281
doi:

Types de publication

Journal Article

Langues

eng

Pagination

bvae051

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.

Auteurs

Alejandra Tapia-Castillo (A)

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
Centro Traslacional de Endocrinología UC (CETREN-UC), Santiago 8330033, Chile.

Cristian A Carvajal (CA)

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
Centro Traslacional de Endocrinología UC (CETREN-UC), Santiago 8330033, Chile.

Jorge A Pérez (JA)

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
Centro Traslacional de Endocrinología UC (CETREN-UC), Santiago 8330033, Chile.

Alejandra Sandoval (A)

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
Centro Traslacional de Endocrinología UC (CETREN-UC), Santiago 8330033, Chile.

Fidel Allende (F)

Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.

Sandra Solari (S)

Department of Clinical Laboratories, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.

Carlos E Fardella (CE)

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
Centro Traslacional de Endocrinología UC (CETREN-UC), Santiago 8330033, Chile.

Classifications MeSH